Early Outcomes Reinforce the Consistency and Reproducibility of Tanruprubart Treatment Effect Previo

Early Outcomes Reinforce the Consistency and Reproducibility of Tanruprubart Treatment Effect Previo

Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of

Expands Financial Capacity as Vonaprument and Tanruprubart Programs Advance Toward Registration Expa

Citizens analyst Jonathan Wolleben initiates coverage on Annexon (NASDAQ:ANNX) with a Market Unde

BRISBANE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutica

Needham analyst Joseph Stringer maintains Annexon (NASDAQ:ANNX) with a Buy and raises the price t

Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of

BRISBANE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutica

Annexon remains a high-risk/high-reward Buy, driven by two near-term blockbuster therapies, notably

BRISBANE, Calif., June 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutica

Annexon, Inc. (ANNX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcr

Annexon NASDAQ: ANNX executives used a Goldman Sachs Healthcare Conference session to outline the co

Annexon NASDAQ: ANNX executives outlined a series of expected clinical and regulatory updates across

BRISBANE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical

BRISBANE, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical

Annexon NASDAQ: ANNX President and CEO Doug Love outlined the company's late-stage pipeline and regu

Annexon, Inc. (ANNX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Goldman Sachs analyst Salveen Richter initiates coverage on Annexon (NASDAQ:ANNX) with a Neutral

CONSHOHOCKEN, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- May is GBS|CIDP Awareness Month and this year ma

Annexon (NASDAQ:ANNX) reported quarterly losses of $(0.23) per share which beat the analyst consensu

Topline Pivotal Phase 3 Data for Vonaprument for the Treatment of Geographic Atrophy (GA) Expected Q

BRISBANE, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical

Annexon (NASDAQ: ANNX) President and CEO Doug Love outlined a series of anticipated clinical and reg

Shares of Annexon, Inc. (NASDAQ: ANNX - Get Free Report) traded down 6.1% on Friday. The company tra

BRISBANE, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutic

The mean of analysts' price targets for Annexon (ANNX) points to a 165.5% upside in the stock. While

US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen

Annexon (NASDAQ:ANNX) reported quarterly losses of $(0.28) per share which beat the analyst consensu

Tanruprubart MAA Filed with Potential to Be the First Targeted Fast-Acting Therapy for Guillain-Barr

Potential to Be the First Targeted Fast-Acting Therapy for GBS, Setting a New Standard of CareBLA Su

Chardan Capital analyst Daniil Gataulin initiates coverage on Annexon (NASDAQ:ANNX) with a Buy ra

Clear Street analyst Bill Maughan initiates coverage on Annexon (NASDAQ:ANNX) with a Buy rating a

Wells Fargo analyst Derek Archila maintains Annexon (NASDAQ:ANNX) with a Overweight and raises th

HC Wainwright & Co. analyst Ananda Ghosh reiterates Annexon (NASDAQ:ANNX) with a Buy and main

Annexon (NASDAQ:ANNX) reported quarterly losses of $(0.34) per share which beat the analyst consensu

New Pilot Appoints Designated Product Development Coordinator to Navigate Regulatory Interactions, R

First Oral Presentation of the Tanruprubart Real-World Evidence (RWE) Study by International Guillai

HC Wainwright & Co. analyst Andrew Fein maintains Annexon (NASDAQ:ANNX) with a Buy and lowers

Needham analyst Joseph Stringer maintains Annexon (NASDAQ:ANNX) with a Buy and lowers the price t

Annexon (NASDAQ:ANNX) reported quarterly losses of $(0.37) per share which missed the analyst consen

Annexon's tanruprubart showed significant and sustained functional gains in Guillain-Barré patie

  First Placebo-Controlled Phase 3 Trial for GBS Presented in AAN Oral Presentation